Published in Anticancer Res on December 01, 2010
The heparan sulfate sulfotransferase 3-OST3A (HS3ST3A) is a novel tumor regulator and a prognostic marker in breast cancer. Oncogene (2016) 0.75
Synthesis and in vivo evaluation of N-ethylamino-2-oxo-1,2-dihydro-quinoline-3-carboxamide for inhibition of intestinal tumorigenesis in APC(Min/+) mice. Bioorg Med Chem Lett (2014) 0.75
Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer (2007) 6.57
Systematic evaluation of microRNA processing patterns in tissues, cell lines, and tumors. RNA (2007) 3.91
Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res (2008) 3.67
Sigma receptors: potential medications development target for anti-cocaine agents. Eur J Pharmacol (2003) 1.79
DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res (2011) 1.73
Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab (2005) 1.56
Reconsidering the length of program accreditation. Am J Pharm Educ (2011) 1.44
miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. Biochem Biophys Res Commun (2011) 1.42
Sepsis induces extensive autophagic vacuolization in hepatocytes: a clinical and laboratory-based study. Lab Invest (2009) 1.41
Identification of a novel putative pancreatic stem/progenitor cell marker DCAMKL-1 in normal mouse pancreas. Am J Physiol Gastrointest Liver Physiol (2010) 1.28
Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition. J Med Chem (2006) 1.19
Tumor suppression by the prohibitin gene 3'untranslated region RNA in human breast cancer. Cancer Res (2003) 1.18
Estrogen receptor-mediated regulation of oxidative stress and DNA damage in breast cancer. Carcinogenesis (2003) 1.16
Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin Cancer Res (2002) 1.15
Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor. Mol Cancer Ther (2008) 1.15
[1,2-13C2]-D-glucose profiles of the serum, liver, pancreas, and DMBA-induced pancreatic tumors of rats. Pancreas (2005) 1.13
Biomarker identification in human pancreatic cancer sera. Pancreas (2008) 1.13
Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. Mol Pharmacol (2005) 1.13
Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes. J Clin Endocrinol Metab (2003) 1.12
Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Mol Pharmacol (2006) 1.12
The final catalytic step of cytochrome p450 aromatase: a density functional theory study. J Am Chem Soc (2005) 1.08
Cocaine up-regulates Fra-2 and sigma-1 receptor gene and protein expression in brain regions involved in addiction and reward. J Pharmacol Exp Ther (2005) 1.07
Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells. J Steroid Biochem Mol Biol (2002) 1.05
Are we producing innovators and leaders or change resisters and followers? Am J Pharm Educ (2012) 1.00
Interrelationships between cyclooxygenases and aromatase: unraveling the relevance of cyclooxygenase inhibitors in breast cancer. Anticancer Agents Med Chem (2006) 0.99
Metabolic biomarker and kinase drug target discovery in cancer using stable isotope-based dynamic metabolic profiling (SIDMAP). Curr Cancer Drug Targets (2003) 0.99
Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist (2008) 0.99
Induction of cardiovascular pathology in a novel model of low-grade chronic inflammation. Cardiovasc Pathol (2007) 0.99
Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7alpha-APTADD to breast cancer cells. Int J Pharm (2010) 0.97
Brain injury: neuro-inflammation, cognitive deficit, and magnetic resonance imaging in a model of blast induced traumatic brain injury. J Neurotrauma (2013) 0.96
Synthesis and biological evaluation of novel sulfonanilide compounds as antiproliferative agents for breast cancer. J Comb Chem (2008) 0.93
Dried plum polyphenols inhibit osteoclastogenesis by downregulating NFATc1 and inflammatory mediators. Calcif Tissue Int (2008) 0.92
Comparison of increased aromatase versus ERα in the generation of mammary hyperplasia and cancer. Cancer Res (2011) 0.92
Synthesis and biological evaluation of selective aromatase expression regulators in breast cancer cells. J Med Chem (2007) 0.90
Expression of prohibitin 3' untranslated region suppressor RNA alters morphology and inhibits motility of breast cancer cells. J Mol Histol (2004) 0.89
SPANosomes as delivery vehicles for small interfering RNA (siRNA). Mol Pharm (2011) 0.88
Medicinal chemistry, metabolic profiling and drug target discovery: a role for metabolic profiling in reverse pharmacology and chemical genetics. Mini Rev Med Chem (2005) 0.88
Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay. J Nat Prod (2006) 0.88
Increased proteasome-dependent degradation of estrogen receptor-alpha by TGF-beta1 in breast cancer cell lines. J Cell Biochem (2003) 0.88
Xanthones from the botanical dietary supplement mangosteen (Garcinia mangostana) with aromatase inhibitory activity. J Nat Prod (2008) 0.87
Molecular MRI assessment of vascular endothelial growth factor receptor-2 in rat C6 gliomas. J Cell Mol Med (2011) 0.87
Suppression of aromatase in human breast cells by a cyclooxygenase-2 inhibitor and its analog involves multiple mechanisms independent of cyclooxygenase-2 inhibition. Steroids (2007) 0.85
Microarray analysis of choroid/RPE gene expression in marmoset eyes undergoing changes in ocular growth and refraction. Mol Vis (2008) 0.84
Novel sulfonanilide analogs decrease aromatase activity in breast cancer cells: synthesis, biological evaluation, and ligand-based pharmacophore identification. J Med Chem (2008) 0.84
Innate responses to systemic infection by intracellular bacteria trigger recruitment of Ly-6Chigh monocytes to the brain. J Immunol (2008) 0.84
Influence of KGF on the progression of pancreatic cancer. Anticancer Res (2009) 0.84
Increasing the DNA damage threshold in breast cancer cells. Toxicol Appl Pharmacol (2002) 0.84
Increased expression of alpha-1-antitrypsin, glutathione S-transferase pi and vascular endothelial growth factor in human pancreatic adenocarcinoma. Am J Surg (2002) 0.84
Human serum albumin-coated lipid nanoparticles for delivery of siRNA to breast cancer. Nanomedicine (2012) 0.83
Utility of nuclear magnetic resonance spectroscopy for pancreatic cancer studies. Pancreas (2012) 0.83
Targeting a methioninase-containing fusion protein to breast cancer urokinase receptors inhibits growth and migration. Anticancer Res (2006) 0.83
Dichotomous metabolism of Enterococcus faecalis induced by haematin starvation modulates colonic gene expression. J Med Microbiol (2008) 0.83
Synthesis and estrogen receptor binding affinities of 7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-ones containing a basic side chain. Bioorg Med Chem Lett (2003) 0.83
Silica-based branched hollow microfibers as a biomimetic extracellular matrix for promoting tumor cell growth in vitro and in vivo. Adv Mater (2013) 0.83
Serum discrimination of early-stage lung cancer patients using electrospray-ionization mass spectrometry. Lung Cancer (2011) 0.83
Natural products as aromatase inhibitors. Anticancer Agents Med Chem (2008) 0.82
KGF-induced motility of breast cancer cells is dependent on Grb2 and Erk1,2. Clin Exp Metastasis (2004) 0.82
Synthesis and characterization of azole isoflavone inhibitors of aromatase. Bioorg Med Chem (2005) 0.82
Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. Clin Breast Cancer (2011) 0.82
Differential efficacy of DOTAP enantiomers for siRNA delivery in vitro. Int J Pharm (2012) 0.81
Lead optimization of 7-benzyloxy 2-(4'-pyridylmethyl)thio isoflavone aromatase inhibitors. Bioorg Med Chem (2005) 0.81
DNA ploidy and markovian analysis of neoplastic progression in experimental pancreatic cancer. J Histochem Cytochem (2003) 0.81
Heme regulates exocrine peptidase precursor genes in zebrafish. Exp Biol Med (Maywood) (2007) 0.81
Antisense KGFR oligonucleotide inhibition of KGF-induced motility in breast cancer cells. Anticancer Res (2004) 0.80
Keratinocyte growth factor stimulates the migration and proliferation of breast cancer cells in a culture wounding model. Pharmacol Res (2002) 0.80
Serum profiling to distinguish early- and late-stage ovarian cancer patients from disease-free individuals. Cancer Invest (2011) 0.80
Synthesis and aromatase inhibitory activity of novel pyridine-containing isoflavones. J Med Chem (2004) 0.80
Identification and characterization of zebrafish ocular formation genes. Genome (2008) 0.80
Role of the azinomycin naphthoate and central amide in sequence-dependent DNA alkylation and cytotoxicity of epoxide-bearing substructures. Org Lett (2002) 0.80
cDNA cloning, DNA binding, and evolution of mammalian transcription factor IIIA. Gene (2002) 0.79
Evaluation of synthetic isoflavones on cell proliferation, estrogen receptor binding affinity, and apoptosis in human breast cancer cells. J Steroid Biochem Mol Biol (2007) 0.79
SiRNA inhibition of ER-alpha expression reduces KGF-induced proliferation of breast cancer cells. Anticancer Res (2008) 0.79
Distinguishing early-stage pancreatic cancer patients from disease-free individuals using serum profiling. Cancer Invest (2011) 0.79
Enhanced motility of KGF-transfected breast cancer cells. Anticancer Res (2006) 0.78
The effect of antiestrogens on TGF-beta-mediated chemotaxis of human breast cancer cells. Anticancer Res (2002) 0.78
Maintaining pharmacy education's research focus as the academy expands. Am J Pharm Educ (2012) 0.78
Distinguishing non-small cell lung adenocarcinoma patients from squamous cell carcinoma patients and control individuals using serum profiling. Cancer Invest (2011) 0.78
Specific and non-specific KGF inhibition of KGF-induced breast cancer cell motility. Anticancer Res (2003) 0.78
Targeting of a novel fusion protein containing methioninase to the urokinase receptor to inhibit breast cancer cell migration and proliferation. Cancer Chemother Pharmacol (2003) 0.77
Isolation and Characterization of Aromatase Inhibitors from Brassaiopsis glomerulata (Araliaceae). Phytochem Lett (2009) 0.77
Distinguishing patients with stage I lung cancer versus control individuals using serum mass profiling. Cancer Invest (2014) 0.76
Systemic molecular and cellular changes induced in rats upon inhalation of JP-8 petroleum fuel vapor. Toxicol Mech Methods (2010) 0.76
Development of keratinocyte growth factor receptor tyrosine kinase inhibitors for the treatment of cancer. Anticancer Res (2008) 0.76
MicroRNA expression profiling in cancer from a bioinformatics prospective. Expert Rev Mol Diagn (2007) 0.76
Rapamycin-loaded immunoliposomes functionalized with trastuzumab: a strategy to enhance cytotoxicity to HER2-positive breast cancer cells. Anticancer Agents Med Chem (2016) 0.75
Selective growth inhibition of cancer cells by L-methioninase-containing fusion protein targeted to the urokinase receptor. Pharmacology (2009) 0.75
Highly efficient cationic ethylphosphatidylcholine siRNA carrier for GFP suppression in modified breast cancer cells. Anticancer Res (2012) 0.75
Wilms' tumor 1 protein and focal adhesion kinase mediate keratinocyte growth factor signaling in breast cancer cells. Anticancer Res (2008) 0.75
Influence of L-methioninase targeted to the urokinase receptor on the proliferation and motility of lung and prostate cancer cells. Anticancer Res (2007) 0.75